Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption
Comprehensive Physiology · 2026
DOI: 10.1002/cph4.70103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Comprehensive Physiology, 2026. Verfasst von Ratchaneevan Aeimlapa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Calcium and Bone Research (COCAB), Faculty of Science, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Vildagliptin, Bone Resorption, Dipeptidyl-Peptidase IV Inhibitors, Osteoclasts. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mahidol University (to R. Aeimlapa), Fundamental Fund through Mahidol University [fiscal year 2024-2026 by National Science Research and Innovation Fund (NSRF); to N. Charoenphandhu], Science and Technology Development Fund by NSRF (ST; to N. Charoenphandhu).
Abstract (Originalsprache)
Increased fracture risk in prediabetes and diabetes mellitus partly arises from bone collagen damage and enhanced bone resorption. Certain antidiabetic agents—particularly thiazolidinediones—paradoxically aggravate bone loss and fractures, especially in postmenopausal women with osteoporosis. However, dipeptidyl peptidase‐4 (DPP‐4) inhibitors (e.g., vildagliptin and omarigliptin) might help prevent diabetic osteopathy, although variable outcomes have been observed due to unknown mechanisms. Herein, we used high‐fat diet‐fed rats to demonstrate that oral administration of vildagliptin for 4 weeks not only alleviated insulin resistance but also improved tibial bone microstructure, as determined by bone histomorphometry. Further in vitro investigations in primary osteoblasts showed that both vildagliptin and omarigliptin similarly increased osteoblast viability, rather than upregulating the expression of osteoblast‐specific genes (e.g., Runx2 and alkaline phosphatase). We also used primary multinucleated osteoclasts to elucidate how the two DPP‐4 inhibitors modulated osteoclast functions. Interestingly, only omarigliptin, but not vildagliptin, reduced the number of TRAP‐positive cells and the mRNA expression of osteoclast‐specific genes (e.g., RANK and cathepsin K). In silico molecular dynamics revealed that omarigliptin and vildagliptin interacted differently with the DPP‐4 homodimer. Transient binding to one chain and tight binding to the other chain of the DPP‐4 homodimer by omarigliptin may be associated with its higher potency in inhibiting bone resorption. In conclusion, DPP‐4 inhibitors could improve bone microstructure, in part by increasing osteoblast viability and inhibiting osteoclast‐mediated bone resorption. Thus, omarigliptin may offer greater benefits to diabetic patients with osteoporosis, as it also helps suppress osteoclastogenesis and bone resorption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Calcium and Bone Research (COCAB), Faculty of Science, Mahidol University, Bangkok, Thailand.
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
- Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.
- Physiology Division, Preclinical Science, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
- Faculty of Allied Health Sciences, Burapha University, Chonburi, Thailand.
- Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.
ORCID-Profile: Jiraporn Panmanee, Siriporn Chattipakorn, Nipon Chattipakorn
Förderung
- Mahidol University (to R. Aeimlapa)
- Fundamental Fund through Mahidol University [fiscal year 2024-2026 by National Science Research and Innovation Fund (NSRF); to N. Charoenphandhu]
- Science and Technology Development Fund by NSRF (ST; to N. Charoenphandhu)
- Central Instrumental Facility (CIF/CNI), Faculty of Science, Mahidol University (to R. Aeimlapa and N. Charoenphandhu)
- Research Assistant Grant from Faculty of Science, Mahidol University (to J. Thongbunchoo)
- Research Cluster Development Fund, Mahidol University (to N. Charoenphandhu)
- NSRF via the Program Management Unit for Human Resources & Institutional Development, Research and Innovation (PMU-B; to N. Charoenphandhu)
- Burapha University-TSRI-NSRF (Fundamental Fund; fiscal year 2025; to K. Wongdee)
Zitieren
APA
Aeimlapa, R., Panmanee, J., Teerapornpuntakit, J., Wongdee, K., Thongbunchoo, J., Panupinthu, N., Svasti, S., Apaijai, N., Sa-Nguanmoo, P., Chattipakorn, S., Chattipakorn, N., & Charoenphandhu, N. (2026). Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption. Comprehensive Physiology. https://doi.org/10.1002/cph4.70103
Vancouver
Aeimlapa R, Panmanee J, Teerapornpuntakit J, Wongdee K, Thongbunchoo J, Panupinthu N, et al. Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption. Comprehensive Physiology. 2026. doi:10.1002/cph4.70103
BibTeX
@article{Aeimlapa2026,
author = {Aeimlapa, Ratchaneevan and Panmanee, Jiraporn and Teerapornpuntakit, Jarinthorn and Wongdee, Kannikar and Thongbunchoo, Jirawan and Panupinthu, Nattapon and Svasti, Saovaros and Apaijai, Nattayaporn and Sa-Nguanmoo, Piangkwan and Chattipakorn, Siriporn and Chattipakorn, Nipon and Charoenphandhu, Narattaphol},
title = {Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption},
journal = {Comprehensive Physiology},
year = {2026},
doi = {10.1002/cph4.70103}
}
EUVIMED